IMmotion151 三期试验最终总生存与分子分析:阿替利珠单抗联合贝伐珠单抗对比舒尼替尼治疗初治转移性肾细胞癌
IMmotion151 是一项多中心、开放标签、三期随机临床试验,比较阿替利珠单抗联合贝伐珠单抗与舒尼替尼在初治转移性肾细胞癌患者中的疗效与安全性。最终分析显示,意向治疗人群和 PD-L1 阳性人群的总生存期在两组间相似,未观察到总生存获益;探索性生物标志物分析提示特定转录组亚型患者可能从联合治疗中获益。
要点
- 最终分析显示,意向治疗人群总生存期在联合组与舒尼替尼组相似(36.1 个月 vs 35.3 个月)。
- PD-L1 阳性人群总生存期在联合组与舒尼替尼组分别为 38.7 个月 vs 31.6 个月。
- 探索性分析显示,T 效应/增殖型、增殖型或小核仁 RNA 转录组特征患者中联合组总生存期有改善趋势(35.4 个月 vs 21.2 个月;HR 0.70;95%CI 0.50-0.98)。
核心结论
- 中期分析时无进展生存期主要终点已达到,但最终分析未观察到阿替利珠单抗联合贝伐珠单抗的总生存获益。
- 生物标志物分析为了解哪些转移性肾细胞癌患者可能从抗 PD-L1 联合抗 VEGF 治疗中获益提供了线索。
研究设计与样本
- IMmotion151 是一项多中心、开放标签、三期随机临床试验,比较阿替利珠单抗联合贝伐珠单抗与舒尼替尼在初治转移性肾细胞癌患者中的疗效与安全性。
- 研究纳入来自 21 个国家 152 个学术医学中心和社区肿瘤实践的患者,共评估 915 例转移性肾细胞癌患者。
- 纳入标准为具有透明细胞或肉瘤样组织学特征的转移性肾细胞癌成人患者,具有可测量病灶(依据实体瘤疗效评价标准 1.1 版)、体能状态及血液学和终末器官功能充分,且有肿瘤组织可供 PD-L1 检测。
- IMmotion151 于 2015 年 5 月 20 日启动,研究正在进行中;本次最终分析时间为 2015 年 5 月 20 日至 2020 年 2 月 14 日。
主要发现
- 意向治疗人群最终分析显示,阿替利珠单抗联合贝伐珠单抗组与舒尼替尼组中位总生存期分别为 36.1 个月 vs 35.3 个月。
- PD-L1 阳性人群最终分析显示,阿替利珠单抗联合贝伐珠单抗组与舒尼替尼组中位总生存期分别为 38.7 个月 vs 31.6 个月。
- 未报告新的安全性信号。
- 探索性分析显示,在肿瘤具有 T 效应/增殖型、增殖型或小核仁 RNA 转录组特征的患者中,阿替利珠单抗联合贝伐珠单抗组与舒尼替尼组中位总生存期分别为 35.4 个月 vs 21.2 个月(风险比 0.70;95%CI 0.50-0.98)。
- 患者平均(四分位距)年龄:阿替利珠单抗联合贝伐珠单抗组为 62(56-69)岁,舒尼替尼组为 60(54-66)岁;669 例(73.1%)为男性,246 例(26.9%)为女性。
关键数值与推荐
- 干预方案:阿替利珠单抗 1200 mg 静脉注射每 3 周一次联合贝伐珠单抗 15 mg/kg 静脉注射每 3 周一次;或舒尼替尼 50 mg 口服每日一次(用药 4 周、停药 2 周)。
- 共同主要终点为 PD-L1 阳性疾病患者的无进展生存期(既往已报告)和意向治疗人群的总生存期。
- 附加探索性结局包括 PD-L1 阳性人群的总生存期、与转录组亚组的关联以及安全性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Interim analyses of the IMmotion151 trial (A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma) reported improved progression-free survival (PFS) for patients with programmed death ligand 1-positive (PD-L1+) metastatic renal cell carcinoma (mRCC) receiving the PD-L1 inhibitor atezolizumab plus the vascular endothelial growth factor (VEGF) inhibitor bevacizumab vs the receptor tyrosine kinase inhibitor sunitinib. Overall survival (OS) results were immature at interim analyses. OBJECTIVE: To report the final OS results, safety, and exploratory biomarker analyses of the association of transcriptomic subgroups with OS in the IMmotion151 trial. DESIGN, SETTING, AND PARTICIPANTS: IMmotion151 was a multicenter, open-label, phase 3 randomized clinical trial that compared the efficacy and safety of atezolizumab plus bevacizumab vs sunitinib in patients with untreated mRCC. IMmotion151 included patients from 152 academic medical centers and community oncology practices in 21 countries. Adult patients with mRCC with components of clear cell or sarcomatoid histologic features, measurable disease (according to Response Evaluation Criteria in Solid Tumors, version 1.1), adequate performance status, hematologic and end organ function, and tumor tissue available for PD-L1 testing were included. IMmotion151 was initiated on May 20, 2015, and the study is ongoing. This final analysis was performed from May 20, 2015, to February 14, 2020. INTERVENTIONS: Receipt of 1200 mg of intravenous (IV) atezolizumab every 3 weeks and 15 mg/kg of IV bevacizumab every 3 weeks or 50 mg orally once daily of sunitinib (4 weeks on and 2 weeks off). MAIN OUTCOMES AND MEASURES: The coprimary end points were PFS (previously reported) in patients with PD-L1+ disease and OS in the intention-to-treat population. Additional exploratory outcomes included OS in the PD-L1+ population, association with transcriptomic subgroups, and safety. RESULTS: The IMmotion151 trial assessed 915 patients with metastatic renal cell carcinoma. Mean (IQR) age was 62 (56-69) years for patients receiving atezolizumab plus bevacizumab and 60 (54-66) years for patients receiving sunitinib; 669 (73.1%) were male and 246 (26.9%) were female. The final analysis showed similar median OS in patients receiving atezolizumab plus bevacizumab vs sunitinib in the intention-to-treat (36.1 vs 35.3 months) and PD-L1+ (38.7 vs 31.6 months) populations. No new safety signals were reported. The additional exploratory outcome of atezolizumab plus bevacizumab vs sunitinib showed improved median OS trends in patients whose tumors were characterized by T-effector/proliferative, proliferative, or small nucleolar RNA transcriptomic profiles (35.4 vs 21.2 months; hazard ratio, 0.70; 95% CI, 0.50-0.98). CONCLUSIONS AND RELEVANCE: The primary end point of PFS was met at interim analyses, although no improvement in OS was observed with atezolizumab plus bevacizumab at the final analysis. Biomarker analyses provided insight into which patients with mRCC may benefit from combined anti-PD-L1 and anti-VEGF therapy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02420821.
引用
- Motzer RJ, Powles T, Atkins MB, et al. Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. JAMA Oncol. 2022. PMID: 34940781. doi:10.1001/jamaoncol.2021.5981
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。